Fig. 6: rhIL-7-hyFc reduces the number of CAR T cells required for the biological effect.
a–e Balb/c mice were first given 1 × 106 A20 tumor cells, followed by cyclophosphamide (Cytoxan) conditioning 1 day prior to receiving mCART19 (5 × 104, 2.5 × 105, or 1.25 × 106 cells per mouse), then given serial injections of rhIL-7-hyFc on days +1, +15, and +29 (n = 4/group). b Overall survival of mice for all groups. c Peripheral blood CAR T cell expansion was measured over time by quantification of CD45.1+GFP+ cells. Each line represents values from one mouse. d B cell numbers were measured over time by quantification CD45.2+ CD19+ cells. Data represented as median ± range. Note that 5 × 104 cells (left panel) are depicted on a different scale. e B cell numbers on day +101 after T cell injection. f NSG mice were injected with 5 × 105 RamosCBR-GFP followed by UCART19 treatment (5 × 104, 2.5 × 105, or 1.25 × 106 cells per mouse) with serial injections of rhIL-7-hyFc on days +1, +15, and +29 (n = 5 mice per group). The top panels represent overall survival, while the bottom panels show serial tumor burden measurements (each line represents one mouse). p Values were calculated using two-sided Wilcoxon test (UCART19 1.25 × 106 + rhIL-7-hyFc vs. UCART19 1.25 × 106 only, p = 0.0039). Source data are provided as a Source data file. **p ≤ 0.01.
